Меню
Идёт набор NCT06559761

Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research

— Наблюдательное Hepatocellular Carcinoma Stage III

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Hepatectomy.
Кому может быть актуально
Состояния в реестре: Hepatocellular Carcinoma Stage III. Базовые параметры: 18 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is a lack of non-invasive and simple indicators to predict the prognosis of HCC patients and assist clinical decision-making. The identification of HCC macroscopic or histopathological classification requires large pathological specimens obtained through surgical resection, but only about 20% of patients are eligible for surgical treatment. Moreover, most liver cancer diagnoses can be confirmed by imaging examinations without relying on pathological results. For patients who have not undergone surgical resection, the lack of histopathological information during treatment means that there is no basis for judging tumor proliferation and obtaining rich prognostic information. Therefore, evaluating the invasion and proliferation ability of HCC based on macroscopic imaging assessment has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. Ultrasound and MRI are ideal entry points as first-line imaging methods for liver cancer diagnosis. This study aims to evaluate HCC macroscopic or histopathological classification based on multimodal imaging (ultrasound, CT, MRI), thereby assessing its invasion and proliferation ability which has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. By analyzing macroscopic image features we aim to explore their cross-scale correlations with HCC macroscopic classification,histopathological classification,and gene molecular typing.

Вмешательства

  • Процедура Hepatectomy
    According to guideline recommended procedure of hepatectomy

Первичные конечные точки

  • Overall survival [Срок оценки: through study completion, an average of 1 year]
Вторичные конечные точки (4)
  • Disease-free survival [Срок оценки: through study completion, an average of 1 year]
  • Imaging features [Срок оценки: through study completion, an average of 1 year]
  • Quantification of immune cells of the resected liver tumour [Срок оценки: through study completion, an average of 1 year]
  • mRNA sequencing data of the resected liver tumour and peritumor parenchyma [Срок оценки: through study completion, an average of 1 year]

Критерии участия

Критерии включения

  • According to the WHO classification, the pathological diagnosis is hepatocellular carcinoma.
  • The initial treatment is curative-intent hepatectomy.
  • There is no evidence of major vascular/hepatic portal invasion, extrahepatic/lymph node metastasis, or other malignant tumors.
  • Age 18-80 years old.

Критерии исключения

· Not meeting any one of the inclusion criteria or being unwilling/unable to follow-up.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 1 центр
  • Chinese PLA General Hospital — Пекин

Идентификаторы

NCT: NCT06559761 · S2024-423

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗